Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL...
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
- Associated Therapies
- -
F2G raises $100M to bring antifungal drug back to FDA
F2G raises $100M to complete Phase 3 testing of olorofim, a novel antifungal for invasive aspergillosis, after FDA rejection. AMR Action Fund and ICG co-led the funding, joined by eight other investors. F2G aims to address FDA concerns and prepare for U.S. launch.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath